Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903)

CONCLUSION: Whilst objective response rates with anastrozole are low, the clinical benefit rate and good tolerance suggests that aromatase inhibitor therapy may have a role in a subset of patients with metastatic LMS and UCS.PMID:34625284 | DOI:10.1016/j.ygyno.2021.09.010

Source: Gynecologic Oncology - October 9, 2021 Category: Cancer & Oncology Authors: R J Edmondson R L O'Connell S Banerjee L Mileshkin P Sykes P Beale A Fisher A Bonaventura D Millan S Nottley C Benson A Hamilton K Sjoquist L Alexander C Kelly K Carty L Divers N Bradshaw M Friedlander PARAGON investigators Source Type: research